LIVZON PHARMA

1513
24.9800.08% ( -0.020 )
Delay Closed: Nov 16, 16:08:11

Overview

LIVZON PHARMA (1513)

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and int...

Open
25.000
High
25.280
Low
24.740
Prev. Close
25.000
Volume
1.23M
Turnover
30.85M
Avg Price
25.047
Bid/Ask Ratio
-50.00%
Amplitude
2.16%
52wk High
30.352
Volume Ratio
1.96
Turnover Ratio
0.41%
52wk Low
18.615
HK Mkt Cap
7.49B
Market CapHKD
22.18B
P/ETTM
12.23
P/EDynamic
11.09
P/EStatic
--
EPSTTM
2.04
EPSDynamic
2.25
EPSStatic
--
BVPS
17.08
P/B
1.46
HK Shares
299.81M
Dividend YieldTTM
11.32%
DividendTTM
2.828
Shares
887.91M
Min lot size
100
Currency
HKD

LIVZON PHARMA Analyst Rating

View more

Forecast & Rating

Oct 29, 2026
Price forecast
HK$26.556.29%
Forecast & RatingHold
4analysts
  • Strong buy50.00%
  • Buy0.00%
  • Hold25.00%
  • Sell25.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Livzon Pharmaceutical (1513.HK) staged a sharp rebound today, closing up 5.34% at HKD 25.64, after opening lower at HKD 24.38. The catalyst was the announcement that Livzon secured a controlling stake in Vietnam's Imexpharm via a tender offer, which overshadowed the Q1 2026 results showing a 4.44% YoY decline in revenue (HKD 3.255 billion) and a 4.08% drop in net profit (HKD 654 million). The stock broke above the HKD 25.40 resistance in the afternoon session and rallied to the intraday high of HKD 25.64. Despite the strong daily move, the stock remains 38.73% below its 52-week high of HKD 41.85 and is down 10.47% year-to-date, though it has reclaimed the 20-day moving average (HKD 25.10). The trailing PE of 10.24x and PB of 1.39x reflect a relatively compressed valuation. However, the full-year 2025 net profit declined 1.8% YoY, and the Q4 2025 net profit plunged 27.56% YoY, suggesting the underlying earnings headwinds are not yet fully resolved.

News